Results 91 to 100 of about 167,688 (127)

Clinical outcomes of agalsidase Beta (fabrazyme) in Chinese fabry disease patients with proteinuria: a case series. [PDF]

Front Pediatr
He Z, Wu Y, Yang H, Li Y, Xu L.
europepmc   +1 more source

Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years' treatment. [PDF]

Orphanet J Rare Dis, 2015
Kampmann C, Perrin A, Beck M.
europepmc   +1 more source

Agalsidase alfa and agalsidase beta in the treatment of Fabry disease: does the dose really matter? [PDF]

Genet Med, 2015
Pisani A, Riccio E, Sabbatini M.
europepmc   +1 more source

Expert Opinion on the Conceptual, Clinical, and Therapeutic Aspects of Fabry Nephropathy: A Nephrologists' Perspective.

Kidney Blood Press Res
Eren N, Turkmen K, Turgut F, Tokgoz B, Inci A, Seyahi N.   +5 more
europepmc   +1 more source

An open-label clinical trial of agalsidase alfa enzyme replacement therapy in children with Fabry disease who are naïve to enzyme replacement therapy. [PDF]

Drug Des Devel Ther, 2016
Goker-Alpan O, Longo N, McDonald M, Shankar SP, Schiffmann R, Chang P, Shen Y, Pano A.   +7 more
europepmc   +1 more source

Prevalence and sociodemographic, clinical, and genetic characteristics of Fabry disease in north-central Chile, 2013-2023. [PDF]

Mol Genet Metab Rep
Royo Martínez S, Castillo-Montes M, Molt F, Cortes Rivera B, Ramírez-Santana M.   +4 more
europepmc   +1 more source

Case Report: Is it COPD? It is Fabry disease: a case in which bronchodilators were briefly used but not continued, prioritizing enzyme replacement therapy. [PDF]

Front Pharmacol
Li Y, Zhu H, Zhan Z, Li G, Huang S, Xiao C, Li Y, Zheng C, Huang F.   +8 more
europepmc   +1 more source

Clinical outcomes in Fabry patients switching to agalsidase beta for renal ineffectiveness of the primary Fabry therapy: a single-centre analysis. [PDF]

Clin Kidney J
Riccio E, Capuano I, Buonanno P, Iaccarino G, Cirami CL, Mignani R, Pieruzzi F, Pisani A.   +7 more
europepmc   +1 more source